The European Alliance of Associations for Rheumatology (EULAR) has updated its recommendations on managing ANCA-associated vasculitis (AAV) based…
Articles by Steve Bryson, PhD
Concerns about the future, their disease’s social and emotional impact, and bodywide symptoms were prominent among those reported by ANCA-associated…
Tavneos (avacopan) effectively reverses severe kidney disease associated with ANCA-associated vasculitis (AAV) compared with standard steroid therapy, according…
Patients with ANCA-associated vasculitis (AAV) have a higher risk of mortality than the general population, especially those who are…
The CoronaVac COVID-19 vaccine has an excellent safety profile, but generates only a moderate immune response in people with…
Intensive care stays are more likely if oxygen-carrying hemoglobin levels are low at hospital admission in adults with kidney disease…
In the year before being diagnosed with ANCA-associated vasculitis (AAV), Medicare beneficiaries had significantly higher use and costs of…
Amgen is the new owner of Tavneos (avacopan), an approved ANCA-associated vasculitis (AAV) therapy, following its successful $3.7…
Immune macrophages or cells that carry the proteins CD163 and/or CD206 play a key role in kidney inflammation in people…
Tavneos (avacopan) has been approved as an add-on therapy for adults in Switzerland with severe, active microscopic polyangiitis (MPA)…